Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives $13.75 Average Target Price from Brokerages

Theravance Biopharma, Inc. (NASDAQ:TBPH) has earned an average rating of “Hold” from the five research firms that are covering the stock, MarketBeat.com reports. Three research analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $13.75.

Several analysts recently commented on TBPH shares. StockNews.com cut shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a research note on Saturday, August 10th. Leerink Partnrs cut Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 6th. Leerink Partners cut Theravance Biopharma from an “outperform” rating to a “market perform” rating and reduced their price objective for the stock from $15.00 to $10.00 in a report on Tuesday, August 6th. TD Cowen lowered their target price on Theravance Biopharma from $10.00 to $9.00 and set a “hold” rating on the stock in a report on Tuesday, August 6th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $15.00 price target on shares of Theravance Biopharma in a research note on Monday, September 16th.

Insider Activity at Theravance Biopharma

In other news, major shareholder Eli Samaha bought 999,800 shares of Theravance Biopharma stock in a transaction on Wednesday, August 7th. The shares were bought at an average cost of $7.80 per share, for a total transaction of $7,798,440.00. Following the acquisition, the insider now owns 9,511,150 shares in the company, valued at approximately $74,186,970. This trade represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 6.90% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in TBPH. China Universal Asset Management Co. Ltd. grew its position in shares of Theravance Biopharma by 64.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 9,409 shares of the biopharmaceutical company’s stock valued at $76,000 after purchasing an additional 3,696 shares during the period. Ballentine Partners LLC purchased a new stake in Theravance Biopharma in the 3rd quarter valued at about $104,000. Squarepoint Ops LLC acquired a new position in shares of Theravance Biopharma during the 2nd quarter valued at about $986,000. Marshall Wace LLP lifted its holdings in shares of Theravance Biopharma by 83.6% during the 2nd quarter. Marshall Wace LLP now owns 297,499 shares of the biopharmaceutical company’s stock worth $2,523,000 after acquiring an additional 135,426 shares during the period. Finally, Bank of Montreal Can boosted its position in shares of Theravance Biopharma by 141.0% in the second quarter. Bank of Montreal Can now owns 160,138 shares of the biopharmaceutical company’s stock worth $1,414,000 after acquiring an additional 93,702 shares during the last quarter. Hedge funds and other institutional investors own 99.10% of the company’s stock.

Theravance Biopharma Stock Down 1.0 %

Shares of NASDAQ:TBPH opened at $8.55 on Friday. Theravance Biopharma has a 52 week low of $7.44 and a 52 week high of $11.71. The company has a 50-day moving average price of $8.22 and a 200 day moving average price of $8.75. The company has a market cap of $415.81 million, a P/E ratio of -9.94 and a beta of 0.25.

Theravance Biopharma (NASDAQ:TBPH) last posted its quarterly earnings results on Monday, August 5th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.25). The business had revenue of $14.26 million during the quarter, compared to analysts’ expectations of $15.81 million. Theravance Biopharma had a negative net margin of 73.61% and a negative return on equity of 21.29%. During the same quarter last year, the firm earned ($0.28) earnings per share. Analysts expect that Theravance Biopharma will post -1.04 EPS for the current year.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.